The once-a-day pill belongs to class of medications called GLP-1 agonists, like Mounjaro, which suppress appetite and make users feel fuller for longer.
A groundbreaking final stage trial showed users could lose more than 10 per cent of their weight after just over a year on the experimental drug orforglipron.